 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

In recent trading, shares of Sight Sciences Inc (SGHT) have crossed above the average analyst 12-month target price of 2.96, changing hands for 3.10/share. When a stock reaches the target...

SGHT Crosses Above Average Analyst Target

Potential Sight Sciences, Inc. ( NASDAQ:SGHT ) shareholders may wish to note that the Independent Chairman, Staffan...

Staffan Encrantz Bought 14% More Shares In Sight Sciences

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lowered its stake in shares of Sight Sciences, Inc. (NASDAQ:SGHT  Free Report) by 37.1% during the 2nd quarter, according to the company in its...

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. Sells 8,033 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)

Sight Sciences, Inc. (NASDAQ:SGHT  Get Free Report) Director Staffan Encrantz acquired 79,234 shares of the companys stock in a transaction dated Monday, November 20th. The stock was...

Sight Sciences, Inc. (NASDAQ:SGHT) Director Staffan Encrantz Purchases 79,234 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT  Get Free Report) saw a significant growth in short interest in October. As of October 31st, there was short interest totalling 1,220,000 shares, a growth of...

Sight Sciences, Inc. (NASDAQ:SGHT) Short Interest Up 17.3% in October

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Sight Sciences, Inc. (NASDAQ: SGHT) ( Sight Sciences ) on behalf of the company's investors...

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sight Sciences, Inc. (NASDAQ: SGHT) and Encourages Investors to Contact the Firm

Sight Sciences (NASDAQ:SGHT  Get Free Report) had its price target decreased by analysts at Morgan Stanley from $4.00 to $3.00 in a research report issued on Wednesday, Benzinga reports. The...

Sight Sciences (NASDAQ:SGHT) Price Target Lowered to $3.00 at Morgan Stanley

STAMFORD, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Sight Sciences, Inc. (Nasdaq: SGHT) ( Sight Sciences or the Company ) on behalf of the Company's investors...

INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Sight Sciences, Inc.; Urges Sight Sciences Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

MENLO PARK, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ( Sight Sciences, or the Company ), an eyecare technology company focused on developing and...

Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023

The event will include a presentation from Brandon Ayres, MD, Wills Eye Hospital and Sight Sciences executive management team on the successful six month results of the SAHARA head-to head randomized...

Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023

Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

Market Cap	$129.19M
Volume (M)	1.00
52-Wk High	$15.30
52-Wk Low	$1.04

SGHT Sight Sciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals